£300m raised for ABV V:
This article was originally published in Clinica
Abingworth has closed what is said to be the largest life sciences venture fund in Europe, rallying a total of £300m ($587m) in investment. Abingworth Bioventures V LP (ABV V), the company's eighth life sciences fund, will invest in bio- and medical technology firms of varying stages of development in Europe and the US. Abingworth says it plans to make over 20 venture investments, ranging between £7.5-20m for each investment.